Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and-10 in spontaneously hypertensive rats with steatohepatitis

Molecular Medicine Reports

Volumn 14, Issue 6, 2016, Pages 5385-5394

  Kozono, Masaya ^a   Uto, Hirofumi ^a,b   Ibusuki, Rie ^a,c   Arima, Shiho ^a   Oda, Kohei ^a   Taguchi, Hiroki ^a   Sasaki, Fumisato ^a   Nasu, Yuichiro ^a   Hashimoto, Shinichi ^a   Setoyama, Hitoshi ^a   Kanmura, Shuji ^a   Numata, Masatsugu ^a   Tsubouchi, Hirohito ^a,d   Ido, Akio ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Miyazaki Aiwa Hospital   (Japan)

^c Departments of International Island and Community Medicine   (Japan)

^d Kagoshima City Hospital   (Japan)

Author keywords

Hypertension; Insulin resistance; Interleukin 10; Interleukin 6; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Regulatory T cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINO ACID; AMLODIPINE; CD4 ANTIGEN; CD68 ANTIGEN; CHOLESTEROL; CHOLINE; GLUCOSE; HYDRALAZINE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; GLUCOSE BLOOD LEVEL; LEUKOCYTE ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXPERIMENTAL HYPERTENSION; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH SODIUM INTAKE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; DIET; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION; IMMUNOLOGY; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHEMOKINE CCL2; DIET; DISEASE MODELS, ANIMAL; HYPERTENSION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-10; INTERLEUKIN-6; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, INBRED SHR; T-LYMPHOCYTE SUBSETS;

EID: 84999115042     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5875     Document Type: Article

References (47)

1. Oda K, Uto H, Mawatari S and Ido A: Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: A review of human studies. Clin J Gastroenterol 8: 1-9, 2015.
2. Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, et al: Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 50: 364-377, 2015.
3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Hepatology 55: 2005-2023, 2012.
4. Angulo P: Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 51: 373-375, 2010.
5. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253, 2011.
6. Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52: 1836-1846, 2010.
7. Than NN and Newsome PN: A concise review of non-alcoholic fatty liver disease. Atherosclerosis 239: 192-202, 2015.
8. Lewington S, Clarke R, Qizilbash N, Peto R and Collins R; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913, 2002.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J and Lisheng L; INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364: 937-952, 2004.
10. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, et al; INTERSTROKE investigators: Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 376: 112-123, 2010.
11. Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, Kure T, Tamai T, Moriuchi A, Sakiyama T, et al: Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol 46: 769-778, 2011.
12. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107: 450-455, 1999.
13. Brea A and Puzo J: Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 167: 1109-1117, 2013.
14. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L and Bolondi L: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: Role of insulin resistance. Gut 53: 1020-1023, 2004.
15. Arima S, Uto H, Ibusuki R, Kumamoto R, Tanoue S, Mawatari S, Oda K, Numata M, Fujita H, Oketani M, et al: Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats. Int J Mol Med 33: 68-76, 2014.
16. Yi B, Titze J, Rykova M, Feuerecker M, Vassilieva G, Nichiporuk I, Schelling G, Morukov B and Choukèr A: Effects of dietary salt levels on monocytic cells and immune responses in healthy human subjects: A longitudinal study. Transl Res 166: 103-110, 2015.
17. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K and Aukrust P: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174, 2006.
18. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN and Feldstein AE: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103: 1372-1379, 2008.
19. Cintra DE, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, Morari J, Gambero A, Saad MJ and Velloso LA: Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 48: 628-637, 2008.
20. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G and Giugliano D: Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 88: 1055-1058, 2003.
21. Braunersreuther V, Viviani GL, Mach F and Montecucco F: Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18: 727-735, 2012.
22. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A and George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40: 46-54, 2004.
23. Sánchez-Lozada LG, Mu W, Roncal C, Sautin YY, Abdelmalek M, Reungjui S, Le M, Nakagawa T, Lan HY, Yu X and Johnson RJ: Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 49: 1-9, 2010.
24. Varagic J, Ahmad S, Voncannon JL, Moniwa N, Simington SW Jr, Brosnihan BK, Gallagher PE, Habibi J, Sowers JR and Ferrario CM: Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 30: 1766-1774, 2012.
25. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E and Abdi R: Human T and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 18: 1093-1102, 2007.
26. González GE, Rhaleb NE, D'Ambrosio MA, Nakagawa P, Liu Y, Leung P, Dai X, Yang XP, Peterson EL and Carretero OA: Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens 33: 144-152, 2015.
27. Bassuk SS, Rifai N and Ridker PM: High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol 29: 439-493, 2004.
28. Ridker PM, Hennekens CH, Buring JE and Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000.
29. Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Yoshihara F, Nakamura S and Kawano Y: Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: Comparison with C-reactive protein. Cytokine 53: 342-346, 2011.
30. Rifai N, Joubran R, Yu H, Asmi M and Jouma M: Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 45: 1967-1973, 1999.
31. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V, García-Zattera MJ, et al: Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 29: 82-88, 2009.
32. Rotter Sopasakis V, Larsson BM, Johansson A, Holmäng A and Smith U: Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47: 1879-1887, 2004.
33. Rotter V, Nagaev I and Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777-45784, 2003.
34. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J and Caron M: Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochem Biophys Res Commun 311: 372-379, 2003.
35. Klover PJ, Clementi AH and Mooney RA: Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417-3427, 2005.
36. Klover PJ, Zimmers TA, Koniaris LG and Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789, 2003.
37. Meda C: The impact of cytokines and chemokines on non-alcoholic fatty liver disease (NAFLD). Biotech Mol Biol Nanomed 2: 15-16, 2014.
38. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB and Kim JK: Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060-1067, 2004.
39. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, et al: Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 58: 2525-2535, 2009.
40. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C and Harrison DG: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
41. Matrougui K, Abd Elmageed Z, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S and Partyka M: Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol 178: 434-441, 2011.
42. Eller K, Kirsch A, Wolf AM, Sopper S, Tagwerker A, Stanzl U, Wolf D, Patsch W, Rosenkranz AR and Eller P: Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 60: 2954-2962, 2011.
43. Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H and Kanatani A: Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 37: 50-57, 2007.
44. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Ables EV and Ferrante AW Jr: C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 59: 916-925, 2010.
45. Kassel KM, Guo GL, Tawfik O and Luyendyk JP: Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. Lab Invest 90: 1794-1804, 2010.
46. Marra F and Tacke F: Roles for chemokines in liver disease. Gastroenterology 147: 577-594, 2014.
47. Itagaki H, Shimizu K, Morikawa S, Ogawa K and Ezaki T: Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol 6: 2683-2696, 2013.